JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...
Costco shoppers spoke to Fox News Digital about the company’s "commitment" to diversity, equity, and inclusion after ...
Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and make those costs more transparent.
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
SaveHealth explores the potential prescription cost savings that can be achieved by leveraging cash prices and discount cards ...
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback